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Abstract
Background: Amyloid plaques, a pathological hallmark of Alzheimer’s disease (AD), are accompanied by activated
microglia. The role of activated microglia in the pathogenesis of AD remains controversial: either clearing Ab
deposits by phagocytosis or releasing proinflammatory cytokines and cytotoxic substances. Microglia can be
activated via toll-like receptors (TLRs), a class of pattern-recognition receptors in the innate immune system. We
previously demonstrated that an AD mouse model homozygous for a loss-of-function mutation of TLR4 had
increases in Ab deposits and buffer-soluble Ab in the brain as compared with a TLR4 wild-type AD mouse model
at 14-16 months of age. However, it is unknown if TLR4 signaling is involved in initiation of Ab deposition as well
as activation and recruitment of microglia at the early stage of AD. Here, we investigated the role of TLR4 signaling
and microglial activation in early stages using 5-month-old AD mouse models when Ab deposits start.
Methods: Microglial activation and amyloid deposition in the brain were determined by immunohistochemistry in
the AD models. Levels of cerebral soluble Ab were determined by ELISA. mRNA levels of cytokines and chemokines
in the brain and Ab-stimulated monocytes were quantified by real-time PCR. Cognitive functions were assessed by
the Morris water maze.
Results: While no difference was found in cerebral Ab load between AD mouse models at 5 months with and
without TLR4 mutation, microglial activation in a TLR4 mutant AD model (TLR4M Tg) was less than that in a TLR4
wild-type AD model (TLR4W Tg). At 9 months, TLR4M Tg mice had increased Ab deposition and soluble Ab42 in
the brain, which were associated with decrements in cognitive functions and expression levels of IL-1b, CCL3, and
CCL4 in the hippocampus compared to TLR4W Tg mice. TLR4 mutation diminished Ab-induced IL-1b, CCL3, and
CCL4 expression in monocytes.
Conclusion: This is the first demonstration of TLR4-dependent activation of microglia at the early stage of b-
amyloidosis. Our results indicate that TLR4 is not involved in the initiation of Ab deposition and that, as Ab
deposits start, microglia are activated via TLR4 signaling to reduce Ab deposits and preserve cognitive functions
from Ab-mediated neurotoxicity.
Background
Alzheimer’s disease (AD) is a progressive dementing dis-
order characterized by Ab-containing amyloid plaques,
intracellular neurofibrillary tangles and degenerating
neurons in the brain. Most mutations in the Ab-protein
precursor (APP) and presenilin (PS1 and PS2) genes,
which are associated with familial AD, increase produc-
tion of Ab, particularly the 42-amino-acid form of Ab
(Ab42) in the brain [1,2]. Aggregated Ab is thought to
be toxic to neurons in the brain and overexpression of
APP with these mutations induces AD-like pathology in
mice. One of the important consequences of Ab depos-
its in the brain is recruitment and activation of micro-
glia. Microglia function as an immunosurveillance cell
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in maintaining immune homeostasis. Accumulating stu-
dies, however, indicate that activated microglia is a dou-
ble-edged sword. They are able to protect neurons from
toxic substances such as aggregated Ab by taking up
and degrading them while activated microglia release
proinflammatory cytokines, chemokines, and reactive
oxygen and nitrogen species, which can be harmful to
synapses and neurons [3-5]. Therefore, it is of great
importance to elucidate the mechanism by which these
phenotypes of activated microglia are regulated for
development of therapeutic strategies.
Toll-like receptors (TLRs) are first-line molecules for
initiating innate immune responses. When activated
through TLR signaling, microglia/macrophages respond
to pathogens and damaged host cells by secreting che-
mokines and cytokines and express co-stimulatory
molecules needed for protective immune responses to
pathogens and efficient clearance of damaged tissues
[6]. Fibrillar Ab has been shown to activate microglia
via cell surface receptor complexes that involve several
toll-like receptors as essential components in vitro
[7-9]. We previously demonstrated that an AD mouse
model homozygous for a nonfunctional (loss-of-func-
tion) mutation of TLR4 had increases in diffuse and
fibrillar Ab deposits as well as buffer-soluble and inso-
luble Ab in the brain as compared with a TLR4 wild-
type AD mouse model (TgAPPswe/PS1dE9 mice) at
14-16 months of age [10]. We also showed that Ab-
induced upregulation of certain cytokines and chemo-
kines in the brain of the same model at 13-15 months
of age was mediated by TLR4 signaling [11]. This AD
mouse model starts to develop Ab deposits in the
brain at around 5 months of age. However, it is not
clear if microglia are activated in the early stages of
AD (reviewed in Wyss-Coray [3]). Heneka et al. [12]
even suggested that microglia may be activated before
any amyloid deposits are formed. Recently, using in
vivo multiphoton microscopy and 5- to 6-month-old
TgAPPswe/PS1dE9 mice, Meyer-Luehmann et al. [13]
reported that amyloid plaques formed extraordinarily
quickly over 24 hours and that within 1-2 days of
appearance of new plaque, microglia were activated
and recruited to the site. On the other hand, Yan et al.
[14] reported that amyloid plaques appeared and grew
over a period of weeks before reaching a mature size
in 6-month-old AD model mice. It is unknown if
TLR4 signaling is involved in activation and recruit-
ment of microglia and if TLR4 signaling is neuropro-
tective or harmful at the early stage of AD when Ab
deposits start. Therefore, in this study we investigated
Ab deposition and microglial activation in the TLR4
mutant and wild-type AD mouse models at 5 months
o fa g ei no r d e rt oe l u c i d a t eap o s s i b l er o l eo fT L R 4
signaling and microglial activation in early stages of
AD pathogenesis.
Methods
Animals
Pathogen-free transgenic mice of an AD model,
TgAPPswe/PS1dE9 mice [B6C3-Tg(APPswe,PSEN1dE9)
85Dbo/J, strain name at Jackson] [15], and B6C3F1 mice
were purchased from Jackson Laboratory (Bar Harbor,
ME). The transgenic mice express chimeric mouse/
human APP with the double mutations (K670N and
M671L) and human PS1 with a deletion of exon 9
found in familial AD patients. The transgenic mice have
been maintained by mating with B6C3F1 mice. C3H/
HeJ mice are highly susceptible to Gram-negative infec-
tion and resistant to bacterial lipopolysaccharide (LPS)
due to a destructive mutation of the TLR4 gene
(TLR4
Lps-d). The TLR4 genotype was determined by
polymerase chain reaction (PCR) followed by restriction
enzyme digestion with Nla III as described previously
[10]. In this study, four experimental groups at the ages
o f5a n d9m o n t h sw e r eu s e d :1 )h o m o z y g o u sT L R 4
mutant TgAPPswe/PS1dE9 transgenic mice (TLR4M
Tg), 2) TLR4 wild-type transgenic mice (TLR4W Tg), 3)
homozygous TLR4 mutant non-transgenic littermates
(TLR4M non-Tg), and 4) TLR4 wild type non-trans-
genic mice (TLR4W non-Tg) (n = 8-11/group at each
age). Half of the mice were deeply anesthetized and per-
fused transcardially with cold PBS followed by 4% paraf-
ormaldehyde and processed for histochemical and
immunohistochemical analyses. Half of the mice were
euthanized and their brains were processed for bio-
chemical analyses. Nine month-old mice (n = 10 -11/
group) were subjected to the Morris water maze test. A
separate set of TLR4W (n = 6) and TLR4M (n = 5) Tg
mice at 5 months of age were used for extraction of
RNA. Another separate set of TLR4W (n = 7) and
TLR4M (n = 4) Tg mice at 9 months of age were also
used for biochemical analyses (protein and mRNA). All
animal protocols used for this study were prospectively
reviewed and approved by the Institutional Animal Care
and Use Committee of the University of Illinois College
of Medicine at Peoria.
Morris water maze behavioral test
Acquisition of spatial learning in the Morris water maze
was assessed during 5 consecutive days. The Morris
water maze consisted of a pool (diameter: 112 cm, wall
height: 75 cm) filled with water (21°C) at a height of 31
cm. Powdered milk was evenly spread over the water
surface in order to camouflage the escape platform (10
cm × 10 cm) made of white plastic and covered with a
wire mesh grid to ensure a firm grip. The pool was con-
tained in a room with visual cues such as light fixtures
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the wall successively in north (N), east (E), south (S),
and west (W) positions, with the escape platform hidden
1 cm below water level in the middle of the NW quad-
rant. An overhead video-camera and SmartTM video-
tracking software (San Diego, CA) were used to estimate
path length and escape latencies in 4 trial sessions for 5
days with approximately 20 min intertrial intervals.
Whenever the mice failed to reach the escape platform
within 1 min, the mice were guided to the platform and
remained on it for 5 seconds. The day after the acquisi-
tion phase, a probe trial was conducted by removing the
platform and placing the mouse next to and facing the
Ns i d e .T h et i m es p e n ti nt h ep r e v i o u s l yc o r r e c tq u a d -
r a n tw a sm e a s u r e df o ras i n g l e1m i nt r i a l .A f t e rt h e
probe trial, the visible platform subtask was conducted,
with the escape platform lifted 1 cm above water level
and shifted to the SE quadrant. A 17 cm high pole was
inserted on top of the escape platform as a viewing aid.
With the exception that the subtest was conducted in a
single day, the same procedure was adopted as with the
acquisition phase.
Immunohistochemistry, histochemistry and quantification
of Ab deposits and activated glial cells
Frozen serial sections (5 μmt h i c k )w e r ec u ta n ds u b -
jected to immunohistochemistry using the avidin-biotin-
peroxidase method (VECTASTAIN ABC Kit). Endogen-
ous peroxidase was eliminated by treatment with 3%
H2O2/10% methanol Tris-buffered saline (TBS) for 20
min at room temperature. After washing with water and
0.1 M TBS (pH 7.4), slides were blocked with 2% bovine
s e r u ma l b u m i n( B S A )a n d2 %g o a ts e r u mi n0 . 1 %t r i -
ton-X-100 TBS (TBST) buffer for 60 min at room tem-
perature to prevent non specific protein binding. The
slides were then incubated with primary antibody 6E10
(1: 2000; Signet Laboratories, Dedham, MA) or CD11b
(1:200; Serotec, MCA711, Raleigh, NC) in 2% BSA, 2%
goat serum TBST overnight at 4°C. The sections were
rinsed in 0.1 M TBST containing 0.1% BSA and incu-
bated with biotinylated secondary antibody anti-mouse
IgG (1: 400) for 6E10 or anti-rat IgG (1:200) for CD11b
in 2% BSA, 1% goat serum TBST for 1 h at room tem-
perature. Finally, the avidin biotin peroxidase method
using 3,3’-diaminobenzidine as a substrate (Vector, Bur-
lingame, CA) was performed according to manufac-
turer’s protocol. For the negative control, slides were
processed with isotype control antibodies (mouse IgG1
for 6E10 and rat IgG2b for CD11b) (BD Biosciences,
San Jose, CA) to ensure specific staining by primary
antibodies. Some sections were counterstained with
hematoxylin. Brain sections were also stained with 1%
thioflavin S followed by destaining in 70% ethanol for
detection of Ab fibrils.
Histomorphometry for quantification of amyloid
deposition and microglial activation was performed
using an Olympus BX61 automated microscope, Olym-
pus Fluoview system and the Image Pro Plus v4 image
analysis software (Media Cybernetics, Silver Spring, MD)
capable of color segmentation and automation via pro-
grammable macros. Each brain section was entirely con-
structed from pictures that were taken using a 10X
objective and 1X eyepiece lens in order to ensure no
overlap. Six coronal brain sections from each mouse
were analyzed, each separated by an approximately 250
μm interval, starting at 1.6 mm posterior to the bregma
to caudal. Areas stained by 6E10, CD11b and thioflavin
S were measured using Image Pro Plus v4 image analy-
sis software and expressed as a percentage of total hip-
pocampus or neocortex examined.
For double-label fluorescence immunohistochemistry,
after quenching autofluorescence by 10 mg/ml sodium
borohydride (NaBH4) and/or 0.05% Sudan Black B,
brain sections were subjected to double-label fluores-
cence immunohistochemistry. For 6E10- and CD11b-
double-label fluorescence, brain sections were incubated
with these antibodies followed by incubation with Alexa
Fluoro 594-conjugated chicken anti-mouse IgG antibody
and Alexa Fluoro 488-conjugated goat-anti-rat IgG anti-
b o d y ,r e s p e c t i v e l y .F o rT L R 4 - ,C D 1 1 b ,C D 4 5 - ,a n d
GFAP-double-label fluorescence, the sections were incu-
bated overnight with rat anti-TLR4/MD2 antibody
(eBioscience, San Diego, CA). After washing, the sec-
tions were incubated with chicken anti-rat IgG antibody
conjugated with Alexa Fluoro 488 (Invitrogen, Carlsbad,
CA) for 2 h. After washing, the same sections were simi-
larly treated with rabbit anti- CD11b (Santa Cruz Bio-
technology), anti-CD45 (Santa Cruz Biotechnology) or
rabbit anti-GFAP (astrocytic marker: G-9269, Sigma)
antibody followed by incubation with chicken anti-rabbit
IgG Alexa Fluoro 594 conjugated secondary antibody
(Invitrogen). Some sections were stained with CD11b
antibody (MCA711) using the avidin-biotin-peroxidase
method as described above and then subjected to thio-
flavin S staining. After washing, the sections were
observed under Olympus IX71 automated fluorescence
microscope. The pictures were taken through an Olym-
pus DP70 digital camera system.
Quantification of buffer soluble brain Ab by ELISA
Using the left cerebral hemispheres, the brain tissues
were dounce-homogenized in carbonate buffer (100 mM
Na2CO3, 50 mM NaCl, pH 11.5) containing protease
inhibitors [10 μg/ml aprotinin and 1 mM 4-(2-ami-
noethyl) benzenesulphonyl fluoride hydrochloride
(AEBSF)] and centrifuged at 16,000 g for 30 min at 4°C.
Protein concentrations in the supernatants were deter-
mined by Bio-Rad Protein Assay (Bio-Rad Laboratories,
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determined by Ab42 and Ab40 enzyme-linked immuno-
sorbent assay (ELISA) kits (Invitrogen) according to the
manufacturer’s protocol. A duplicate sample from each
mouse was used for quantification.
Quantification of cytokine and chemokine mRNA by real-
time PCR
The neocortex and hippocampus were separately iso-
lated and soaked in RNAlater
® Tissue Collection: RNA
Stabilization Solution (Ambions, Austin, TX) at 4°C
overnight and then moved to -80°C. These tissues were
homogenized in Trizol reagent (Invitrogen) for isolation
of RNA. RNA samples were treated with RNase-Free
DNase (Qiagen, Valencia, CA) for 15 min at room tem-
perature, and total RNA was purified using QIAGEN
RNeasy columns. Complementary DNA (cDNA) was
generated from 2 μg total RNA in a total volume of 20
μlu s i n gS u p e r S c r i p t
® III First-Strand Synthesis Kit
(Invitrogen) according to the manufacturer’sp r o t o c o l .
mRNA levels of interleukin (IL)-1a,I L - 1 b,I L - 4 ,I L - 6 ,
tumor necrosis factor (TNF)-a, transforming growth
factor (TGF)-b,i n t e r f e r o n( I F N ) - g, CCL2 (MCP-1),
CCL3 (MIP-1a), CCL4 (MIP-1b) and CCL6 (C10) in the
neocortex and hippocampus were determined by real-
time PCR using an iCycler Thermal Cycler (Bio-Rad,
Hercules, CA). Complementary DNA (cDNA) was
amplified using FastStart SYBR Green Master mix
(Roche Applied Science, Indianapolis, IN) with primers
listed in Table 1. The PCR amplifications were per-
formed as follows: 10 min preincubation at 95°C to acti-
vate the FastStart Taq DNA polymerase, 40 cycles of
denaturation at 95°C for 15 s, and primer annealing and
extension for 1 min at 60°C. PCR product melting
curves were examined to confirm the homogeneity of
PCR products. mRNA levels of cytokines and chemo-
kines were normalized by subtracting cycle threshold
(Ct) values obtained with GAPDH mRNA and expressed
as 2
-ΔCt [ΔCt = Ct (cytokine or chemokine) - Ct
(GAPDH)].
Isolation of CD11b
+ splenocytes by flow cytometry
Spleens were individually isolated from 2-month old
TLR4M and TLR4W Tg mice. Single cell suspension of
splenocytes was prepared by homogenizing a spleen tis-
sue in 10 ml of RPMI 1640 medium and forcing cells
through a cell strainer with 70 μm pores. Splenocytes
were centrifuged at 200 g for 5 min and suspended with
0.8 ml ACK lysing buffer (UAB Comprehensive Cancer
Center) to lyse red blood cells. Cell suspension was cen-
trifuged again at 300 g for 5 min and final cell pellets
were suspended in 1 × PBS containing 1% BSA. Cells
were adjusted to 1 × 10
7 cells/ml and incubated with 1
μg/ml of PE rat anti-mouse CD11b (BD Pharmingen) at
4°C for 40 min in the dark. Then, cells were washed
twice with 1 × PBS containing 1% BSA and centrifuged
at 300 g for 5 min. The pellets were re-suspended in 1
× PBS containing 1% BSA at a concentration of 1 × 10
7
cells/ml. The cells were sorted into CD11b
+ and
CD11b
-/low population by the FACSCalibur System (Bec-
ton-Dickinson Bioscience, Rockville, MD).
Treatment of CD11b
+ monocytes with fibrillar Ab
Synthetic Ab42 was purchased from Anaspec (Anaspec
Inc, San Jose, CA). Fibrillar Ab was prepared as described
previously [16]. The peptide was dissolved in 1 mM hexa-
fluoroisopropanol (Sigma) and then dried under vacuum
in a Speed Vac (Savant, Holbrook, NY). The residual pep-
tide was re-suspended in dimethyl sulfoxide to a concen-
tration of 5 mM. Fibrillar Ab was made by adding 10
mM HCl to a concentration of 100 μM and incubated at
37°C for 24 h. CD11b
+ splenocytes from TLRM and
TLR4W Tg mice were plated at the density of 2.5 × 10
5
cells/ml and incubated with 1 μM fibrillar Ab for 4 h.
Table 1 DNA primer sequences for real-time PCR
Gene Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
IL-1a AGGAGAGCCGGGTGACAGTA AACTCAGCCGTCTCTTCTTCAGA
IL-1ß TGGTGTGTGACGTTCCCATT CAGCACGAGGCTTTTTTGTTG
IL-4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA
IL-10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT
TNF-a TCCAGGCGGTGCCTATGT CGATCACCCCGAAGTTCAGTA
TGF-b TGACGTCACTGGAGTTGTACGG GGTTCATGTCATGGATGGTGC
IFN-g TGAACGCTACACACTGCATCTTG GTTATTCAGACTTTCTAGGCTTTCAATG
CCL2 TGAATGTGAAGTTGACCCGT AAGGCATCACAGTCCGAGTC
CCL3 CCTCTGTCACCTGCTCAACA GATGAATTGGCGTGGAATCT
CCL4 CCCACTTCCTGCTGTTTCTC GAGGAGGCCTCTCCTGAAGT
CCL6 GCCACACAGATCCCATGTAA GCAATGACCTTGTTCCCAGA
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reagent as described above. Complementary DNA
(cDNA) was generated from 1 μg total RNA in a total
volume of 20 μlu s i n gS u p e r S c r i p t
® III First-Strand
Synthesis Kit according to the manufacturer’sp r o t o c o l .
The experiment was performed in triplicate for each con-
dition. mRNA levels of IL-1a,I L - 1 b, IL-6, CCL3, CCL4
were determined by real-time PCR as described above.
Statistical analysis
Data were expressed as mean ± standard error of the
mean (SEM). Intergroup differences were assessed by a
repeated measures analysis of variance (ANOVA) and
two-tailed Student’s t-test for normally distributed data.
For the probe trial of the Morris water maze, the Mann-
Whitney rank sum test was used for comparison. P ≤
0.05 was considered statistically significant.
Results
TLR4 mutation does not influence Ab load in the brain of
an AD mouse model at 5 months of age but diminishes
microglial activation
TLR4W Tg mice start to develop Ab deposits in the
brain around the age of 5 months. To investigate if TLR4
signaling is involved in initiation of Ab deposition and
microglial activation at the early stage of AD, we deter-
mined Ab load and microglial activation in the TLR4W
(n = 5) and TLR4M (n = 7) Tg mice at 5 months. Diffuse
and fibrillar Ab deposits were detected by immunohisto-
chemistry using 6E10 antibody that specifically reacts
with human Ab (Figure 1A and 1B) and were expressed
by average percentages of areas showing Ab immunor-
eactivity in the cerebral cortex (Figure 1E). No difference
was found in Ab load between TLR4W (0.243 ± 0.045%)
and TLR4M (0.196 ± 0.030%) Tg mice (P > 0.05).
Activated microglia/myeloid cells in the cerebral cor-
tex were immunostained for expression of CD11b (Mac-
1) (Figure 1C and 1D) and the immunoreactive areas
were quantified (Figure 1F). CD11b-immunoreactivity
(0.237 ± 0.043%) in TLR4W Tg mice was greater than
that (0.087 ± 0.011%) in TLR4M Tg mice (P = 0.001).
The ratio of CD11b-immunoreactive area to 6E10-
immunoreactive area in TLR4W Tg mice (0.921 ±
0.133) was greater than that in TLR4M Tg mice (0.459
± 0.049, P = 0.006) (Figure 1G).
To confirm this reduction in CD11b-positive microglia in
TLR4M Tg mice, we carried out double immunofluores-
cence staining of brain sections from Tg mice using anti-
CD11b antibody (green) and anti-Ab antibody (red) (Figure
1 Ha n d1 I ) .M o s tA b deposits in TLR4W Tg mice were clo-
sely associated with microglia showing high expression of
CD11b and some degree of overlap was found in double
immunofluorescence images (Figure 1H), suggesting uptake
of Ab by activated microglia. On the contrary, expression of
CD11b in microglia closely associated with Ab deposits was
limited in TLR4 M Tg mice (Figure 1I).
To investigate if the TLR4 mutation alters production
of Ab in the brain, we determined levels of buffer-solu-
ble Ab40 and Ab42 by ELISA in early stages of amyloi-
dogenesis. There was no difference between TLR4W (n
= 4) and TLR4M (n = 6) Tg mice at 5 months of age in
the cerebral buffer-soluble Ab40 (24.1 ± 3.4 and 27.3 ±
8.6 pg/mg protein, respectively) and Ab42 (19.1 ± 4.0
and 17.6 ± 7.2 pg/mg protein, respectively) content.
TLR4 mutation increases Ab deposits as well as soluble
Ab42 in the brain of an AD mouse model at 9 months of
age
We previously reported that cerebral Ab load increased
in TLR4M Tg mice as compared to TLR4W Tg mice at
14-16 months of age [10] but we did not find such an
increase at 5 months of age. Therefore, we further
examined Ab load in these AD mouse models at 9
months of age. Diffuse and fibrillar Ab deposits were
detected by immunohistochemistry using 6E10 antibody
(Figure 2A and 2B) and Ab loads were expressed by
average percentage of areas showing Ab immunoreactiv-
ity in the hippocampus and neocortex (Figure 2G and
2H). The Ab loads in the neocortex (2.20 ± 0.15%) and
hippocampus (1.42 ± 0.27%) increased in TLR4M Tg
mice as compared to TLR4W Tg mice (1.40 ± 0.15%, P
< 0.005 for the neocortex and 1.08 ± 0.06%, P < 0.01 for
the hippocampus, n = 6 for each group). Fibrillar Ab
deposits were visualized by thioflavin S fluorescence
(Figure 2C and 2D). The Ab load in TLR4M Tg mice
(0.728 ± 0.064% for the neocortex and 0.601 ± 0.080%
for the hippocampus) was greater than that in TLR4W
Tg mice (0.487 ± 0.056%, P = 0.021 for the neocortex
and 0.368 ± 0.033%; P = 0.026 for the hippocampus, n =
6 for each group) (Figure 2I and 2J).
Activated microglia/myeloid cells in the neocortex and
hippocampus were immunostained for expression of
CD11b (Figure 2E and 2F) and immunoreactive areas
were quantified (Figure 2K and 2L). There was no dif-
ference in expression levels of CD11b between TLR4W
and TLR4M Tg mice. No difference was found between
the two groups in the ratios of CD11b-immunoreactive
area to 6E10-immunoreactive area (Figure 2M and 2N).
Levels of buffer-soluble Ab in the cerebrum of
TLR4M Tg mice increased at 14-16 months of age as
compared to TLR4W Tg mice [10] but not at 5 months
of age. Therefore, we further determined levels of buf-
fer-soluble Ab in the two Tg mouse groups at 9 months
by Ab40- and Ab42-specific sandwich ELISA. The cere-
bral buffer-soluble Ab42 content in TLR4M Tg mice
(597.8 ± 21.3 pg/mg protein, n = 4) was significantly
higher than that in TLR4W Tg mice (278.3 ± 79.3 pg/
mg protein, n = 4, P < 0.01) while there was no
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Page 5 of 14Figure 1 TLR4 mutation did not influence Ab load but diminished microglial activation in an AD mouse model at 5 months of age.A b
deposits in the brains of TLR4W Tg (A) and TLR4M Tg (B) mice were visualized by anti-Ab antibody (6E10). Activated microglia are visualized by
anti-CD11b antibody in TLR4W Tg (C) and TLR4M Tg (D) mice. The inset image (C) is a higher magnification of the area indicated by the square.
(E) Cerebral Ab plaques are visualized by 6E10 and average percentages of Ab-immunoreactive areas in the cerebral cortex are shown as a bar
graph (means ± SEM). Average percentages of immunoreactive areas in the cerebral cortex for an activated microglial marker, CD11b (F), are
shown as a bar graph (means ± SEM). The ratio of CD11b-immunoreactive area to 6E10-immunoreactive area in the cerebral cortex (G) are
shown as a bar graph (means ± SEM). Brain sections from 5-month-old TLR4W Tg (H) and TLR4M Tg (I) mice were subjected to double-label
fluorescence immunohistochemistry using anti-CD11b (green) antibody and 6E10 (red). *P ≤ 0.05. Scale bars 200 μm for A through D, 50 μm for
H and I, and 10 μm for the inset.
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Page 6 of 14Figure 2 TLR4 mutation increased Ab load in the brain of an AD mouse model at 9 months of age.A b plaques in the brains of TLR4W
Tg (A and C) and TLR4M Tg (B and D) mice were visualized by 6E10 immunohistochemistry and thioflavin S fluorescence, respectively. Average
percentages of areas showing Ab immunoreactivity and fluorescence in the neocortex (G and I) and hippocampus (H and J) are shown as a bar
graph (means ± SEM). Activated microglia were detected by anti-CD11b antibody in TLR4W Tg (E) and TLR4M Tg (F) mice. The inset images (E
and F) are a higher magnification of the areas indicated by the squares. Average percentages of CD11b-immunoreactive areas in the neocortex
(K) and hippocampus (L) are shown as a bar graph (means ± SEM). The ratio of CD11b-immunoreactive area to 6E10-immunoreactive area in the
neocortex (M) and hippocampus (N) are shown as a bar graph (means ± SEM). *P < 0.05. Scale bars 200 μm for A through F and 10 μm for the
insets.
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cerebral buffer-soluble Ab40 content (183.2 ± 24.5 pg/
mg protein and 218.6 ± 32.0 pg/mg protein, respectively,
P > 0.05) (Figure 3).
Amyloid plaques are associated with activated microglia
expressing TLR4
Ab deposits have been shown to be closely associated with
activated microglia and reactive astrocytes. To assess
whether Ab deposition in the brain can recruit microglia
and astrocytes expressing TLR4, we performed a colocali-
zation analysis using anti-CD11b, anti-CD45 (a transmem-
brane protein tyrosine phosphatase specific for migratory
leukocytes including activated microglia), anti-GFAP (an
astrocyte-specific intermediate filament protein) and anti-
TLR4 antibodies. Brain sections from 9-month-old
TLR4W Tg mice were double-stained with anti-TLR4
antibody and 1of 3 antibodis (anti-CD11b, anti-CD45, or
anti-GFAP antibody). One brain section was statined with
both anti-CD11b antibody and thioflavin S. Almost all
fibrillar Ab deposits stained with thioflavin S were closely
accompanied by CD11b-immunoreactive microglia (Figure
4A, B and 4C). Immunofluorescence staining of the brain
sections revealed that CD11b- and CD45-positive micro-
glia co-expressed TLR4 (Figure 4D, E and 4F for CD11b,
and G, H and I for CD45) whereas limited expression of
TLR4 was found in GFAP-positive astrocytes (Figure 4J, K
and 4L).
TLR4 mutation makes an AD mouse model vulnerable to
cognitive deficits in the Morris water maze
We previously reported that the APPswe/PS1dE9 trans-
genic mice had spatial learning and memory deficits by
the Morris water maze at 12 months of age but not at 7
months [17,18]. Because soluble Ab42 is thought to be
neurotoxic and levels of soluble Ab42 in the brains of 9-
month-old TLR4M Tg mice increased compared to
those in TLR4W Tg mice, we evaluated the effects of
the TLR4 mutation on spatial learning and memory by
the Morris water maze in the AD mouse model at 9
months of age. In the acquisition phase, three-way
ANOVA with transgene and TLR4 as main factors and
days as the repeated measure revealed significant TLR4
(F (1, 36) =5 . 4 6 ,P < 0.05) and day (F (1, 144) = 19.72, P <
0 . 0 0 1 )e f f e c t sf o rp a t hl e n g t h sa sw e l la sT L R 4( F(1, 36)
= 5.50, P < 0.05) and day (F (1, 144) = 32.84, P < 0.001)
effects for escape latencies. Paired comparisons by one-
way ANOVA revealed higher latencies on days 2 (F (1,
18) = 8.33, P < 0.01) and 3 (F (1, 18) = 4.85, P < 0.05) and
higher path lengths on days 1 (F (1, 18) =4 . 5 8 ,P <0 . 0 5 )
and 3 (F (1, 18) =4 . 5 8 ,P < 0.05) by TLR4M Tg mice (n
= 10) than TLR4W Tg mice (n = 10), indicating that
mutated TLR4 led to poorer scores than wild-type TLR4
in APP/PS1 transgenic mice. Moreover, TLR4M Tg
mice had higher escape latencies than TLR4M non-Tg
mice (n = 10) on days 1 (F (1, 18) = 5.97, P < 0.05) and 3
(F (1, 18) =7 . 8 5 ,P < 0.02) (Figure 5A and 5B). No other
group differences were found in the acquisition phase or
in either the probe or visible platform subtasks. These
data indicate that mutated TLR4 impaired acquisition in
the early not the late stage of training and spared long-
term memory, visual acuity, and swimming abilities.
Ab fibrils upregulate expression of certain cytokines and
chemokines via TLR4 signaling in the hippocampus and
splenic monocytes
Induction of TLR signaling by its ligands in macro-
phages/microglia culminates in activation of transcrip-
tion factors that upregulate expression of certain
cytokines and chemokines, which are required for pro-
tective immune responses to pathogens and efficient
clearance of damaged tissues. Fibrillar Ab can activate
microglia through interaction with cell surface receptor
complexes whose essential components include TLR4
[7-9]. Therefore, we determined levels of cytokines and
chemokines in 5- and 9-month-old TLR4M (n = 5 and
4, respectively) and TLR4W (n = 6 and 7, respectively)
Tg mice, which are possibly modulated by TLR signal-
ing in the AD pathogenesis. Cycle threshold (Ct)
values of mRNAs for the cytokines and chemokines
are provided in Table 2. At 5 months of age, mRNA
levels of IL-6 in TLR4M Tg mice decreased compared
with TLR4W Tg mice in the hippocampus (2-fold, P =
0.01) but the difference in the neocortex was not sig-
nificant (P = 0.18) (Figure 6). There were no differ-
ences in mRNA levels of IL-1a,I L - 1 b,T G F - b, CCL2,
CCL3, CCL4, and CCL6 between the two groups at 5
months of age. At 9 months, mRNA levels of IL-1b
(2.5-fold, P < 0.0005), CCL3 (3.5-fold, P < 0.05), and
CCL4 (3-fold, P < 0.05) decreased in TLR4M Tg mice
as compared to those in TLR4W Tg mice in the hip-
pocampus (Figure 6). In the neocortex, however, such
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Figure 3 TLR4 mutation increased cerebral buffer-soluble Ab42
in an AD mouse model at 9 months of age. The cerebral buffer-
soluble Ab42 and Ab40 contents in TLR4W and TLR4M Tg mice
were quantified by ELISA. The results are shown as bar graphs
(means ± SEM pg/mg total protein). *P < 0.01.
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Page 8 of 14Figure 4 Ab plaques were surrounded by activated microglia expressing TLR4. A brain section from a TLR4W Tg mouse was stained with
thioflavin S for fibrillar amyloid deposits (B) and immunostained with anti-CD11b antibody using avidin-biotin immuno-peroxidase method and
DAB (A). (C) is a superimposition of (A) and (B), demonstrating that fibrillar Ab deposits are closely accompanied by CD11b-positive microglia.
Brain sections from a TLR4W Tg mouse were labeled with anti-TLR4 antibody (green) (E and H) followed by staining with anti-CD11b (red) (D) or
anti-CD45 (red) (G) antibody. The yellow colors in the superimposed images of (F) and (I) between (D) and (E) and between (G) and (H) indicate
co-localization of TLR4 with activated microglia (CD11b and CD45), respectively. Overlap between astrocytes detected by anti-GFAP antibody
(red) (J) and TLR4 (green) (K) is occasionally found in the merged picture (L). Scale bars 50 μm.Asterisks indicate amyloid plaques.
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Page 9 of 14ad e c r e a s ei n9 - m o n t h - o l dT L R 4 MT gm i c ew a sf o u n d
only in the CCL3 mRNA levels (5-fold, P =0 . 0 1 ) .C e r -
ebral mRNA levels of IL-4, TNF-a,a n dI F N - g were
too low to satisfactorily make comparisons under the
current experimental conditions.
Microglia are cells of myeloid origin and considered to
be macrophages/monocytes in the central nervous sys-
tem. Therefore, we have isolated CD11b
+ splenocytes
(monocytes) from 2-month-old TLR4W and TLR4 M
Tg mice by fluorescence-activated cell sorting (FACS).
After treating CD11b
+ cells with fibrillar Ab, expression
levels of cytokines and chemokines were determined by
real-time PCR as described above. Ct values of mRNA
for cytokines and chemokines are shown in Table 3.
mRNA levels of IL-1a,I L - 1 b, IL-6, CCL3 and CCL4 in
fibrillar Ab-treated TLR4M CD11b
+ cells were signifi-
cantly lower than those in fibrillar Ab-treated TLR4W
CD11b
+ cells (P < 0.005 for all measures) (Figure 7).
Discussion
Microglial activation and differentiation is complex and
can produce diverse phenotypes depending upon their
environments, pathogenic contexts, activating ligands
and genetic backgrounds [19]. In AD, activated micro-
glia can be beneficial by clearing toxic Ab assemblies
and secreting neurotrophic factors [4,5]. On the other
hand, activated microglia can be synapto- and neuro-
toxic by initiating and advancing the disease [3-5]. Little,
however, is known about the mechanisms by which
microglial activation states are orchestrated in AD.
Here, we show that a nonfunctional mutation in the
TLR4 gene diminished Ab-induced microglial activation
in AD model mice at 5 months of age when the AD
model mice start to develop Ab deposits in the brain.
There was no difference in the cerebral Ab deposits and
buffer-soluble Ab amounts between TLR4W and
TLR4M Tg mice in the very early stages of b-amyloido-
sis. Thus, TLR4 signaling did not alter Ab production
and the onset of Ab deposition. We also demonstrate
that 9-month-old TLR4M Tg mice had increases in the
amounts of cerebral Ab deposits and soluble Ab42,
which were associated with special learning deficits and
reduced expression of CCL3. Thus, activation of micro-
glia through TLR4 appears to be neuroprotective.
A
B
Figure 5 An AD mouse model with TLR4 mutation was more
vulnerable to cognitive impairment as assessed in the Morris
water maze. Total cumulated scores per day for escape latencies
(sec) (A) and path length (cm) (B) (means ± SEM) are shown during
acquisition of the hidden platform task at 9 months of age. Spatial
learning was impaired in TLR4M Tg mice as shown by increases in
escape latencies and path length (*P < 0.05; **P < 0.01). No
difference was found between any other groups.
Table 2 Cycle threshold (Ct) values of mRNAs
IL-1a IL-1ß IL-6 TGFß CCL2
(MCP-1)
CCL3
(MIP-1a)
CCL4
(MIP-1ß)
CCL6
(C10)
GAPDH
9M
Neocortex
TLR4M 25.7 ± 0.35 28.8 ± 0.49 29.0 ± 0.44 22.3 ± 0.39 27.4 ± 0.74 28.1 ± 0.42 28.6 ± 0.37 23.5 ± 0.50 13.2 ± 0.22
TLR4W 24.5 ± 0.38 27.5 ± 0.30 28.6 ± 0.15 21.7 ± 0.30 27.2 ± 0.33 24.7 ± 0.36 26.2 ± 0.29 22.4 ± 0.23 13.4 ± 0.30
Hippocampus TLR4M 25.5 ± 0.49 29.8 ± 0.57 29.2 ± 0.41 21.4 ± 0.20 28.03 ± 0.25 27.6 ± 0.34 29.2 ± 0.40 23.1 ± 0.22 12.8 ± 0.33
TLR4W 24.1 ± 0.29 27.4 ± 0.09 28.2 ± 0.13 20.6 ± 0.07 27.7 ± 0.29 24.7 ± 0.37 26.6 ± 0.30 20.7 ± 0.24 12.6 ± 0.35
5M
Neocortex
TLR4M 29.2 ± 0.50 29.5 ± 0.54 29.1 ± 0.45 23.2 ± 0.41 31.6 ± 0.93 27.4 ± 0.51 28.9 ± 0.42 24.24 ± 0.23 15.5 ± 0.45
TLR4W 27.5 ± 0.20 28.9 ± 0.24 27.1 ± 0.28 21.9 ± 0.10 29.5 ± 0.83 26.8 ± 0.13 27.7 ± 0.44 22.6 ± 0.29 14.6 ± 0.43
Hippocampus TLR4M 26.2 ± 0.34 29.2 ± 0.33 28.2 ± 0.06 22.0 ± 0.40 28.3 ± 0.49 26.9 ± 0.62 29.0 ± 0.48 23.8 ± 0.34 14.1 ± 0.22
TLR4W 24.9 ± 0.24 28.4 ± 0.24 27.2 ± 0.15 21.3 ± 0.22 26.9 ± 0.32 25.7 ± 0.54 28.5 ± 0.40 23.2 ± 0.69 14.0 ± 0.06
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Figure 6 TLR4 mutation decreased expression levels of IL-1b, CCL3 and CCL4 in an AD mouse model at 9 months of age. mRNA levels
of cytokines and chemokines in the neocortex and hippocampus from TLR4W and TLR4M Tg mice at age 5 and 9 months were determined by
real-time PCR using cDNA prepared by reverse-transcription of mRNA. mRNA levels of cytokines and chemokines were normalized by subtracting
cycle threshold (Ct) values obtained with GAPDH mRNA and are shown as 2
-ΔCt [ΔCt = Ct (cytokine or chemokine) - Ct (GAPDH)] (means ±
SEM). *P < 0.05.
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Page 11 of 14We previously reported that APPswe/PS1dE9 trans-
genic mice had spatial learning and memory deficits at
12 months of age but not at 7 months as assessed by
the Morris water maze [17,18]. In line with these obser-
vations spatial learning deficits were not found in
TLR4W Tg mice at 9 months of age but were apparent
in TLR4M Tg mice of the same age. Thus, mice with
t h eT L R 4m u t a t i o na p p e a r e dm o r ev u l n e r a b l et oc o g n i -
tive deficits associated with the APPswe/PS1dE9 trans-
genes. The cognitive deficits in 9-month-old TLR4M Tg
mice may be attributable to an increase in the cerebral
Ab load, particularly soluble Ab42. Ab42 is thought to
be more pathogenic than Ab40 and an increase in the
Ab42 to Ab40 ratio stabilizes toxic soluble Ab oligomers
[20]. Soluble oligomeric Ab species have been identified
as synapto- and neurotoxic forms of Ab rather than
insoluble amyloid fibrils [21-23]. Soluble oligomeric Ab
levels are elevated in the brains of AD patients and cor-
relate with cognitive dysfunction [24]. Meyer-Luehmann
et al. [13] hypothesize that amyloid plaques act as a
local source of soluble Ab causing neuritic alterations. It
is thus tempting to hypothesize that activated microglia
through TLR4 ligation protect neurons from toxic oligo-
meric Ab which is released or produced from amyloid
plaques by clearing Ab oligomers and deposits.
W ef o u n da ni n c r e a s ei nt h ec e r e b r a lA b load in
T L R 4 MT gm i c ea t9m o n t h so fa g eb u tn o ta t5
months. Microglial activation associated with Ab
deposits diminished in TLR4M Tg mice at 5 months.
Our results are concordant with the observations from
in vitro experiments by several other groups [7,9,25]
that fibrillar Ab activates microglia through interaction
with its cell surface receptor complex to facilitate Ab
phagocytosis and further, that TLR4 is required for
fibrillar Ab-induced activation of microglia as part of
the receptor complex in vitro. However, there is no dif-
ference in the Ab load between TLR4W and TLR4M Tg
mice at 5 months when amyloid deposition starts. Ab
clearance by activated microglia in vivo m a yb es l o wa s
suggested by Meyer-Luehmann et al. [13]. Thus, the dif-
ference in the Ab load may be indiscernible in early
stages of Ab deposition and gradually become evident
by 9 months of age.
Fibrillar Ab activates microglia/monocytes through
TLR4 and induces expression of cytokines in vitro
[7,9,24]. In spite of diminished microglial activation
detected by CD11b expression in 5-month-old TLR4M
Tg mice, levels of cytokine and chemokine expression
were not altered except IL-6 in the hippocampus.
Because Ab deposition starts to develop in this AD
mouse model at 5 months, the differences in the cyto-
kine and chemokine levels may be too small to be
detected. Alternatively, CD11b-positive microglia do not
substantially produce the investigated cytokines and che-
mokines at early stages of b-amyloidosis in vivo.
Expression levels of IL-1b and CCL4 in 9-month-old
TLR4M Tg mice reduced in the hippocampus but not
in the neocortex. A consistent decrease in both hippo-
campus and neocortex of 9-month-old TLR4M Tg mice
was found only in expression levels of CCL3. CCL3 is a
member of the CC chemokine subfamily and its main
function is the recruitment of leukocytes to the site of
inflammation. Ab has been shown to induce microglial
CCL3 expression and monocyte migration in vitro
Table 3 Cycle threshold (Ct) values of mRNAs from
CD11b positive cells
IL-1a IL-6 CCL4 CCL3 IL-1b GAPDH
TLR4M 27.7 ±
0.10
31.2 ±
0.40
29.3 ±
0.76
28.1 ±
0.13
24.6 ±
0.06
20.2 ±
0.09
TLR4W 25.9 ±
0.08
26.4 ±
0.46
26.2 ±
0.15
23.2 ±
0.06
21.6 ±
0.25
19.1 ±
0.06
Figure 7 TLR4M monocytes express less IL-1a, IL-1b, IL-6, CCL3 and CCL4 than TLR4W monocytes after fibrillar Ab stimulation. CD11b
+
splenocytes (monocytes) from 2-month-old TLR4W and TLR4 M Tg mice were collected by FACS. After treatment with fibrillar Ab for 4 hours,
mRNA levels of cytokines and chemokines were determined by real-time PCR. mRNA levels of cytokines and chemokines were normalized by
subtracting cycle threshold (Ct) values obtained with GAPDH mRNA and are shown as 2
-ΔCt [ΔCt = Ct (cytokine or chemokine) - Ct (GAPDH)]
(means ± SEM). *P < 0.005.
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Page 12 of 14[26-28]. Intrahippocampal injection of Ab also induces
microglial CCL3 expression and transendothelial migra-
tion of T cells in rodents [29-31]. Thus, a decrease in
CCL3 expression in TLR4M Tg mice may diminish
recruitment of bone-marrow derived microglia/mono-
cytes. Bone-marrow derived microglia/macrophages
have been shown to be very efficient in restricting the
growth of amyloid plaques but resident microglia are
not [32]. Furthermore, exercise decreases the cerebral
Ab load in an AD mouse model, which is accompanied
by an increase in cerebral CCL3 levels [33]. Here, we
demonstrated TLR4 mutation diminished fibrillar Ab-
induced CCL3 expression in monocytes, suggesting that
TLR4 signaling may play an important role in recruit-
ment of microglia/monocytes. Therefore, the decrease in
CCL3 expression in 9-month-old TLR4M Tg mice may
contribute to the increase in the cerebral Ab load. It
would be interesting to determine the role of CCL3 in
cerebral b-amyloidosis by under- and over-expression of
CCL3 in the brains of AD mouse models.
TLR2 deficiency (TLR2-/-) in an AD mouse model
also increased soluble Ab42 in the brain and exacer-
bated cognitive impairments [34]. Furthermore, injection
of CpG oligodeoxynucleotides, a TLR9 ligand, reduced
Ab load in the brain and restored cognitive deficits in
an AD mouse model [35,36]. These results suggest that
activation of TLRs can be a therapeutic option for AD.
Conclusion
In summary, our results suggest that TLR4 signaling is
not involved in initiation of Ab deposition and that
microglia are activated and recruited in response to Ab
deposition via TLR4 signaling to promote Ab clearance,
resulting in protection of neurons from Ab-mediated
neurotoxicity. Because Ab fibrils upregulate expression
of CCL3 in myeloid cells through TLR4 activation,
CCL3 may be involved in microglial recruitment and Ab
clearance. Thus, activation of microglia via TLR4 in
early stages of AD pathogenesis is neuroprotective and
TLR4 signaling pathways offer potential therapeutic
targets.
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